Semaglutide and Cardiovascular Outcomes. Reply

N Engl J Med. 2024 Feb 22;390(8):768-769. doi: 10.1056/NEJMc2400414.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Obesity

Substances

  • semaglutide
  • Glucagon-Like Peptides